Hypertension and atrial fibrillation

Athanasios Manolis, Giuseppe Mancia(University of Milano-Bicocca), Gianfranco Parati(IRCCS Istituto Auxologico Italiano), Gregory Y.H. Lip(Medical University of Białystok), Roland E. Schmieder(Universitätsklinikum Erlangen), Renata Cífková(Brigham and Women's Hospital), António Coca, Sverre E. Kjeldsen(Oslo University Hospital), Krzysztof Narkiewicz(Gdańsk Medical University), Costas Tsioufis(National and Kapodistrian University of Athens), Serap Erdine(University of Milan), Enrico Agabiti Rosei(University of Brescia), Josep Redón

Journal of Hypertension

December 20, 2011

10.1097/hjh.0b013e32834f03bf

Cited by 199

Related Papers

2018 ESC/ESH Guidelines for the management of arterial hypertension

|European Heart Journal|2018|10.5k

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

|New England Journal of Medicine|2017|9.1k

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

|The Lancet|2002|5.4k

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

|The Lancet|2021|3.8k

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

|The Lancet|2003|3.8k